{"organizations": [], "uuid": "948e9a2416f4a8756ccf05e2641588324bd21b7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sancilio-pharma-says-sickle-cell-t/brief-sancilio-pharma-says-sickle-cell-treatment-receives-ema-orphan-drug-status-idUSFWN1RG0FT", "country": "US", "domain_rank": 408, "title": "BRIEF-Sancilio Pharma Says Sickle Cell Treatment Receives EMA Orphan Drug Status", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.404, "site_type": "news", "published": "2018-04-03T20:16:00.000+03:00", "replies_count": 0, "uuid": "948e9a2416f4a8756ccf05e2641588324bd21b7f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sancilio-pharma-says-sickle-cell-t/brief-sancilio-pharma-says-sickle-cell-treatment-receives-ema-orphan-drug-status-idUSFWN1RG0FT", "ord_in_thread": 0, "title": "BRIEF-Sancilio Pharma Says Sickle Cell Treatment Receives EMA Orphan Drug Status", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-sancilio pharma", "sentiment": "negative"}, {"name": "reuters) - sancilio pharmaceuticals co inc", "sentiment": "neutral"}, {"name": "scd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - Sancilio Pharmaceuticals Co Inc :\n* COMPANY ANNOUNCES ALTEMIA™ RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE (SCD)\n* ‍SPCI PLANS TO PRESENT DETAILED DATA FROM COMPLETED SCOT PHASE 2 STUDY IN PEER REVIEWED JOURNALS & SCIENTIFIC CONFERENCES​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T20:16:00.000+03:00", "crawled": "2018-04-04T12:13:04.037+03:00", "highlightTitle": ""}